Caris Life Sciences, Inc.
CAI Nasdaq· Services-Medical Laboratories
Last close · Oct 23, 2026
$32.00
KIRA · Stoqly’s AI analyst, in plain words
- Caris Life Sciences, Inc. had $812M of revenue in fiscal 2025, up 97.0% on the year before.
- Its operating margin was 5.6%, up 67.9 pts: of every 100 in sales, about 6 is left after running the business.
- Caris Life Sciences, Inc. lost $68.1M in fiscal 2025.
- Free cash flow was $66.9M in fiscal 2025, 8.2% of revenue.
- Caris Life Sciences, Inc. returned $0.1M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 371.0%.
- Caris Life Sciences, Inc. has $420M more cash than debt.
Market cap
$9.1B
P/E
3.8x
Revenue
$812M
Net income
−$68.1M
Free cash flow
$66.9M
Operating margin
5.6%
Caris Life Sciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+97.0%
Yes. Sales grew 97.0% last year.
Does it make a profit?
−8.4%
No. It lost money last year.
Does profit turn into cash?
8.2%
Partly. 8.2% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
3.8x
One share costs 3.8 times its yearly profit per share.
What Caris Life Sciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- Caris Life Sciences, Inc.
- CIK
- 0002019410
Caris Life Sciences, Inc. · CAI
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $306M | $412M | $812M |
| Revenue growth | — | 34.7% | 97.0% |
| Operating margin | −104.4% | −62.4% | 5.6% |
| Net income | −$341M | −$282M | −$68.1M |
| Net margin | −111.5% | −68.4% | −8.4% |
| Diluted EPS | −$13.24 | −$10.66 | −$3.22 |
| Cash | |||
| Cash from operations | −$276M | −$245M | $83.2M |
| Capital expenditure | $22.3M | $8.4M | $16.3M |
| Free cash flow | −$298M | −$254M | $66.9M |
| FCF margin | −97.5% | −61.5% | 8.2% |
| Share buybacks | $0.0M | $0.0M | $0.1M |
| Share count change | — | 1.6% | 371.0% |
| Debt and strength | |||
| Cash and short-term investments | — | $66.2M | $799M |
| Debt incl. finance leases | — | $373M | $379M |
| Shareholders' equity | −$2.1B | −$2.5B | $577M |
| Net debt / EBITDA | — | — | −6.2x |
| Current ratio | — | 1.3x | 7.8x |
| Interest coverage | −10.1x | −5.1x | 0.8x |
| Returns and quality | |||
| Return on capital | — | — | 22.7% |
| Return on tangible equity | — | — | −96.4% |
| Piotroski F-score | — | — | 5 |
| Altman Z'' | — | −31.7 | −0.9 |
Insiders bought, 12 months
$1.6M
4 insiders
Insiders sold, 12 months
$28.9M
4 insiders
Of sales under plans
6%
$1.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Caris Life Sciences, Inc. · CAI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $32.00 a share, the company is worth $9.1B: 3.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0002019410). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.